Low iodine diet does not improve the efficacy of radioiodine for the treatment of Graves' disease

ABSTRACT Objective: Consuming a low-iodine diet (LID) is a widely accepted practice before administering radioiodine ( 131 I) to evaluate and to treat thyroid disease. Although this procedure is well established for the management of patients with differentiated thyroid cancer, its use in patients with benign disease is unclear. So, we aimed to evaluate the influence of a LID on the outcome in patients with Graves' disease (GD) treated with 131 I. Subjects and methods: We evaluated 67 patients with GD who were divided into 2 groups: one group (n = 31) consumed a LID for 1-2 weeks, and the second group (n = 36) was instructed to maintain a regular diet (RD). Results: The LID group experienced a 23% decrease in urinary iodine after 1 week on the diet and a significant 42% decrease after 2 weeks on the diet. The majority (53%) of the patients in the LID group had urinary iodine levels that were consistent with deficient iodine intake. However, there was no difference in the rate of hyperthyroidism's cure between the LID and the RD groups 6 months after 131 I therapy. Furthermore, the therapeutic efficacy did not differ in patients with varying degrees of sufficient iodine intake (corresponding urinary iodine levels: < 10 μg/dL is deficient; 10-29.9 μg/dL is sufficient; and > 30 μg/dL is excessive). Conclusion: In the present study, we demonstrated that although a LID decreased urinary iodine levels, those levels corresponding with sufficient or a mild excess in iodine intake did not compromise the therapeutic efficacy of 131 I for the treatment of GD. Arch Endocrinol Metab. 2015;59(6):501-

The comparative study of weight-heigth distribution in Turner syndrome patients in different cytogenetic situations

Objetivos: O presente trabalho tem por objetivo investigar a influência da condição citogenética no desenvolvimento pôndero-estatural em pacientes portadores da Síndrome de Turner (ST) Metodologia: A casuística consistiu de 32 pacientes com ST. As análises cromossômicas foram realizadas em 50 metáfases de linfócitos do sangue periférico. Esses pacientes foram classificados de acordo com os resultados do exame de cariótipo em 3 grupos: I – Monossomia de X, 53,12%; II – Alterações estruturais do cromossomo X, 12,50%; III – Mosaicismo, 34,34% dos pacientes. Foi calculada a diferença percentual entre as médias de estatura e peso dos mesmos e estes dados comparados à população normal (Marcondes, 1971). Os valores obtidos foram submetidos à análise estatística. Resultados: Os grupos I e III apresentaram déficit de peso e estatura em relação aos normais, sendo o déficit de peso comprovadamente maior que o estatural. No grupo II, os resultados sugerem que isso também ocorra, não havendo porém, significância estatística. Também observamos que o déficit pôdero-estatural do grupo III foi menos acentuado em relação ao grupo I. Conclusões: Estes resultados indicam que a situação citogenética exerce influência no desenvolvimento pôndero-estatural em portadores da ST, sendo o déficit estatural mais acentuado nos casos de monossomia de X

Low iodine diet does not improve the efficacy of radioiodine for the treatment of Graves’ disease

Objective Consuming a low-iodine diet (LID) is a widely accepted practice before administering radioiodine (131I) to evaluate and to treat thyroid disease. Although this procedure is well established for the management of patients with differentiated thyroid cancer, its use in patients with benign disease is unclear. So, we aimed to evaluate the influence of a LID on the outcome in patients with Graves’ disease (GD) treated with131I. Subjects and methods We evaluated 67 patients with GD who were divided into 2 groups: one group (n = 31) consumed a LID for 1-2 weeks, and the second group (n = 36) was instructed to maintain a regular diet (RD). Results The LID group experienced a 23% decrease in urinary iodine after 1 week on the diet and a significant 42% decrease after 2 weeks on the diet. The majority (53%) of the patients in the LID group had urinary iodine levels that were consistent with deficient iodine intake. However, there was no difference in the rate of hyperthyroidism’s cure between the LID and the RD groups 6 months after 131I therapy. Furthermore, the therapeutic efficacy did not differ in patients with varying degrees of sufficient iodine intake (corresponding urinary iodine levels: 30 μg/dL is excessive). Conclusion In the present study, we demonstrated that although a LID decreased urinary iodine levels, those levels corresponding with sufficient or a mild excess in iodine intake did not compromise the therapeutic efficacy of131I for the treatment of GD